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1. Introduction
Liver cancer is the fifth and seventh most frequently diagnosed cancer worldwide in men and
women, respectively, but the second most frequent cause of cancer death in men [1]. In
addition, hepatocellular carcinoma (HCC) represents the major histological subtype of
primary liver cancers, accounting up to 90% of the total liver cancer burden worldwide [2].
The incidence of HCC has increased significantly over the past 10 years and is expected to
increase because of the actual high prevalence of viral hepatitis C-seropositive individuals and
also because of the known long latency period to HCC development from the initial hepatitis
C virus (HCV) infection, which may take 2-3 decades [3]. Despite of the varied treatment
options, the prognosis of HCC remains poor. Thus, estimated 5-year survival rates are in the
range of 26% to 50%, and disease-free survival is 13% to 29% [4]. At present, systemic chemo‐
therapy is quite ineffective in HCC treatment, and is also known to express the multidrug-
resistance gene MDR-1 [5]. Therefore, is necessary to identify and characterize molecular
abnormalities of clinical significance in HCC. Besides the heterogeneity of different HCC
subtypes, these tumors may use different cellular pathways and oncogenic mechanisms at
different development stages, and this is of essential importance to develop biologically-based
clinical trials.
2. Steroid hormone receptors and hepatocellular carcinoma
Although sex differences in liver cancer may be attributed to differences in lifestyle [6-8], there
are several epidemiological and experimental studies suggesting that HCC might be, in part,
hormone-related. Liver cancer is predominantly a male disease, with approximately three
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times higher incidence and mortality among men than women [9]. This male predominance
is further supported by the fact that chronic liver disease progresses more rapidly to cirrhosis
in males than in females, and therefore cirrhosis-derived HCC is largely seen in men and
postmenopausal women disease [10].
The role of estrogens in modulating morphological and physiological features of liver became
evident in early 1970s when a possible correlation between occurrence of hepatic neoplasms
and use of oral contraceptives was suggested [11-12]. On the basis of these data, several in
vitro and in vivo studies have explored the importance of sex hormones in HCC. Animal model-
based studies indicate that sex hormones play a key role in tumor progression, showing that
ovarian estrogens protect against tumor progression, whereas androgens promote tumori‐
genesis [13-15]. It has been reported that the protective effect of estrogens against chemically
induced liver tumors is mediated by prolactin (PRL) through liver prolactin receptors (PRLR)
[16-18]. Nevertheless, the precise role of male and female sex hormones and their receptors in
HCC remains still poorly understood. There is not enough information regarding the mecha‐
nism of estrogen and androgen in HCC.
Estrogen and androgen mediate their biological functions through binding to their specific
receptors, the estrogen receptor (ER) and the androgen receptor (AR). Both ER and AR belong
to the nuclear receptors family that, as transcription factors, regulate the expression level of
several genes such as those involved in triggering immune responses, cell proliferation and
apoptosis [19-21]. Therefore, sex hormones play a key role in normal physiology of organs
other than these of the reproductive system.
Variable expressions of ER and AR has been found in normal liver and HCC using different
methods, such as immunohistochemistry, enzyme-immuno assays, or determining mRNA
levels (Table 1 and Table 2 give the details of these studies for ER and AR, respectively), which
indicate a relationship between sex hormones and pathogenesis of HCC. The percentage of
positivity for these receptors varied between the different studies [22]. These differences may
be due to several methodological aspects, such as differences in the origin of the studied
patients populations, sample types or technologies determining the receptor expression. In a
recent study, we determined the expression of sex hormones receptors in 31 HCC patients by
immunohistochemistry using tissue micro-arrays technology [23]. Our results demonstrate a
wide variability in the immunohistochemical values for steroid receptors among HCCs: 67.7%
of tumors stained positively for AR, 51.6% for ER and 83.8% for progesterone receptor (PgR),
but, among the positive cases, immunostaining score values for each protein were largely
variable.
Reference Protein /mRNA Type of livertissue Method Localization n
%
positive
cases
Country Year
[122] ER protein Normal BA cytosolic 4 100 United Kingdom 1978
[123] ER protein Normal BA - 3 100 Germany 1978
[124] ER protein Normal BA - 2 100 United States 1982
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Reference Protein /mRNA Type of livertissue Method Localization n
%
positive
cases
Country Year
[125] ER protein Normal BA - 6 100 Germany 1982
[126] ER protein Normal BA - 6 100 United States 1983
[127] ER protein Normal BA cytosolic andnuclear 4 100 United Kingdom 1983
[128] ER protein Surrounding BA cytosolic 30 43 Japan 1986
[129] ER protein Non-cancerous BA cytosolic andnuclear 7 43 Japan 1986
[130] ER protein Non-cirrhotic EIA cytosolic 12 12 Japan 1987
[131] ER protein Normal - 2 2 Japan 1988
[132] ER protein Surrounding BA cytosolic 17 65 Japan 1989
[133] ER protein Surrounding 22 64 Japan 1989
[134] ER protein Surrounding BA cytosolic 5 100 Japan 1990
[135] ER protein Normal BA 9 9 United States,Italy 1991
[52] ER protein Non-cancerous BA cytosolic 26 42 Spain 1993
[136] ER mRNA Non-cancerous ISH 13 54 Italy 1993
[137] ER mRNA Peritumoral RT-PCR - 32 88 Korea 2006
[124] ER protein HCC BA cytosolic 5 100 United States 1982
[127] ER protein HCC BA cytosolic andnuclear 5 100 United Kingdom 1983
[138] ER protein HCC IHC cytosolic 10 10 Singapore 1984
[128] ER protein HCC BA cytosolic 30 40 Japan 1986
[139] ER protein HCC BA cytosolic andnuclear 8 13 Japan 1986
[130] ER protein HCC EIA cytosolic 13 38 Japan 1987
[132] ER protein HCC BA cytosolic 19 37 Japan 1989
[24] ER protein HCC BA cytosolic 66 39 Japan 1990
[134] ER protein HCC BA cytosolic 6 17 Japan 1990
[140] ER protein HCC BA cytosolic 21 48 Japan 1991
[141] ER protein HCC BA cytosolic andnuclear 9 89
United States,
Italy 1991
[135] ER protein HCC BA cytosolic andnuclear 9 89
United States,
Italy 1991
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Reference Protein /mRNA Type of livertissue Method Localization n
%
positive
cases
Country Year
[52] ER protein HCC EIA cytosolic 26 15 Spain 1993
[136] ER protein HCC IHC - 15 0 Italy 1993
[136] ER mRNA HCC ISH - 15 73 Italy 1993
[142] ER mRNA HCC RT-PCR - 14 57 Italy 1995
[25] ER protein HCC EIA cytosolic 33 39 Germany 1997
[143] ER protein HCC IHC cytosolic 71 24 China 1997
[144] ER mRNA HCC RT-PCR - 40 70 Italy 1998
[145] ER mRNA HCC RT-PCR - 42 60 Italy 2003
[146] ER protein HCC IHC cytosolic andnuclear 45 71
United States/
Koreans 2004
[147] ER protein HCC IHC - 28 39 China 2004
[147] ER mRNA HCC RT-PCR - 28 89 China 2004
[137] ER mRNA HCC RT-PCR - 32 100 Korea 2006
[148] ER protein HCC IHC - 66 5 Mexico 2007
[23] ER protein HCC IHC Nuclear 31 52 Spain 2007
ER: Estrogen receptor; HCC: Hepatocellular carcinoma; BA: Binding assay; EIA: Enzyme immunoassay; ISH: In situ
hybridization; RT-PCR: Reverse transcriptase-polymerase Chain reaction for ERα wild type; IHC: Immunohistochemistry.
Table 1. Estrogen expression in normal liver and hepatocellular carcinoma tissue samples.
Reference Protein /mRNA Type of livertissue Method Localization n
% positive
cases Country Year
[127] AR protein Normal BA cytosolic andnuclear 4 0
United
Kingdom 1983
[139] AR protein Non-cancerous BA cytosolic andnuclear 6 17 Japan 1986
[132] AR protein Non-cancerous BA cytosolic 17 65 Japan 1989
[133] AR protein Surrounding 21 33 Japan 1989
[134] AR protein Surrounding BA cytosolic 10 80 Japan 1990
[135] AR protein Normal - - 9 100 United States,Italy 1991
[137] AR mRNA Peritumoral RT-PCR 32 100 Korea 2006
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Reference Protein /mRNA Type of livertissue Method Localization n
% positive
cases Country Year
[127] AR protein HCC BA cytosolic andnuclear 5 100
United
Kingdom 1983
[138] AR protein HCC IHC cytosolic 10 50 Singapore 1984
[149] AR protein HCC BA cytosolic 19 74 Japan 1985
[150] AR protein HCC BA cytosolic andnuclear 5 100
United
Kingdom 1985
[139] AR protein HCC BA cytosolic andnuclear 8 50 Japan 1986
[151] AR protein HCC BA cytosolic 13 100 UnitedKingdom 1988
[132] AR protein HCC BA cytosolic 19 37 Japan 1989
[27] AR protein HCC BA cytosolic 45 69 Japan 1989
[134] AR protein HCC BA cytosolic 11 64 Japan 1990
[140] AR protein HCC BA cytosolic 21 86 Japan 1991
[135] AR protein HCC BA cytosolic andnuclear 9 100
United States,
Italy 1991
[152] AR protein HCC BA cytosolic 5 100 Japan 1992
[52] AR protein HCC BA cytosolic 26 54 Spain 1993
[28] AR protein HCC BA cytosolic 43 65 Spain 1995
[23] AR protein HCC IHC nuclear 31 68 Spain 2007
[129] AR mRNA HCC ISH - 22 73 Italy 1994
[153] AR mRNA HCC RT-PCR - 38 89 Italy 2002
[137] AR mRNA HCC RT-PCR - 32 100 Korea 2006
AR: Androgen receptor; HCC: Hepatocellular carcinoma; BA: Binding assay; ISH: In situ hybridization; RT-PCR: Reverse
transcriptase-polymerase Chain reaction; IHC: Immunohistochemistry.
Table 2. Androgen receptor expression in normal liver and hepatocellular carcinoma tissue samples.
Several studies have analyzed the relationship between ER or AR and clinicopathological
parameters from HCCs patients and their clinical outcome (Table 3). In general, ER expression
was associated with higher tumor aggressiveness and/or worse prognosis in HCC patients
[24-26], whereas AR expression was negatively associated with recurrence [27-29]. It is
remarkable the finding that the presence of the ERα variant has been associated with shortened
overall survival in patients with resectable HCC [30,26].
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3. Steroid receptors and hepatitis virus
It is of special interest the interaction between sex estrogen receptors and viral proteins in
hepatitis B virus (HBV) and hepatitis C virus (HCV)-induced HCC. It has been reported that
a HBV protein (HBx) interacts with ERα. HBx is a multifunctional protein involved in
neoplastic transformation in cultured cells and in HCC induction in transgenic mice. Both HBx
and vERα (Delta 5 deletion variant of ERα) have additive effects on suppressing ERα trans‐
activation [31]. In addition, it was reported that tamoxifen inhibits ERα actions and suppresses
HCV genome replication [32], which may be of potential interest to develop new anti-HCV
strategies based on anti-ER drugs. On the other hand, higher serum androgen concentrations
or a specific AR gene, which leads to higher AR activities, have also been associated to higher
risk in HBV-mediated HCC [33-34]. Likewise, it has been reported that the combination of
male gender and HBV infection had a significant synergistic effect on HCC progression [35].
Most recently, Ming-Heng et al. found that hepatic AR increases the HBV viral titer by
enhancing HBV RNA transcription through direct binding to the androgen response element
near the viral core promoter. This activity forms a positive feedback mechanism with the
cooperation of its downstream target, the HBx protein, to promote hepatocarcinogenesis. In
addition in these same study administration of a chemical compound that selectively degrades
AR, ASC-J9, was able to suppress HCC tumor size in a transgenic HBV mouse model that
developed HCC upon exposure to a low dose of N'-N'-diethylnitrosamine (DEN). These results
demonstrate that targeting the AR, rather than the androgen, could be developed as a new
therapy to battle HBV-induced HCC [36].
Reference Protein /mRNA
clinicopathological
parameters Correlation n year country
[128] ER protein
Serum alpha-fetoprotein, HBV
profile, tumor histology,
carcinoembryonic antigen
- 30 1986 Japan
[132] ER and ARprotein
Serum alpha-fetoprotein,
Histopathology, HBV markers - 19 1989 Japan
[24] ER protein
Sex, age, alcohol
consumption, hepatic
function, other liver disease,
tumor size, hepatic resection,
tumor recurrence, long-term
survival rate
ER- patients showed higher
rate of resection and larger
tumor size
66 1990 Japan
[49] ER and ARprotein Local recurrence
AR expression was associated
with intrahepatic recurrence 78 1995 Japan
[25] ER protein Survival after curativeresection
ER+ tumor have a negative
effect on patient survival after
curative resection
28 1997 Germany
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Reference Protein /mRNA
clinicopathological
parameters Correlation n year country
[26] ER mRNA Survival Wild type ERs tumors showedlong survival in patients 96 2000 Italy
[132] AR protein Recurrence and survival rate
AR+ patients showed higher
recurrence rates.
AR- patients showed better
survival rates.
45 1989 Japan
[28] AR protein Tumor size and tumorrecurrence
AR expression correlated with
smaller tumor size. Higher
tumor recurrence in AR+
surrounding tissues.
43 1995 Spain
[29] AR protein Tumor size and survival time
AR+ tumor correlated with
higher tumor size and lower
survival rates.
32 1998 China
ER: Estrogen receptor; AR: Androgen receptor
Table 3. Relationship between estrogen or androgen receptors with clinicopathological parameters and clinical
outcome of patients with HCC.
4. Endocrine therapy in hepatocellular carcinoma
Considering both the epidemiologic and the experimental data supporting the sex steroids
influence in growth and progression from HCCs, different clinical studies analyzed if endo‐
crine therapy could be interesting in advanced disease. Table 4 gives details of some of these
studies. Trials using several agents, such as the anti-estrogen tamoxifen, megestrol acetate,
progestin, the gonadotropin releasing hormone (GnRH) agonist leuprorelin and the anti-
androgen flutamide have been uniformly disappointing [37-40]. At present, experts have
concluded that hormonal manipulation should not be a part of the current management of
patients with HCC [41-42]. However, it is possible that the rational design of an endocrine
therapy requires a more complete understanding of the role of sex hormones in the tumorigenic
process and how hormones and organ systems interact during this process [18], in addition to
careful selection of the new studies patient populations, since patient stratification based on
gender may uncover signals of activity of hormonal therapy in these settings. Notably, it has
been shown that the anti-estrogens tamoxifen and raloxifene, behave differently in different
tissues, producing estrogen-agonist activity in one tissue while behaving as an antagonist in
another [43-44]. In addition, in vitro studies in the liver cell line Hep3B, indicate that raloxifene
induces the insulin-like growth factor (IGF-I) gene transcription, whereas estradiol or tamox‐
ifen inhibits it [45]. On the other hand, the lack of hormone efficacy in these clinical studies, in
terms of tumor growth and survival, could be due to either a low expression of ER or AR in
HCC or to mutated receptors expression. Therefore, further studies will be necessary to
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improve patient selection on the basis of gender, ER tumor expression and their functional
status. With regard to this latter aspect, considering that PgR is an estrogen inducible protein,
it led us to consider that this steroid receptor could be a possible marker of ER functional status
in HCC, to select candidate patients to an anti-estrogenic therapy. In addition, we demon‐
strated that PgR expression have a prognostic implication in patients with resected HCCs,
being a factor associated with better prognostic [23], which is a clinical finding previously
demonstrated in breast cancer [46-47]. This finding is very important considering also our
reported positive association between PgR expression and HCV infection [23], which repre‐
sents an increasing aetiology of HCC in our patient’s population [3].
Several data suggest that blocking AR may be interesting in HCC therapy. Studies in animal
models suggest that increased hepatic AR expression correlated with accelerated tumor
development [48], or even AR expression was associated with intrahepatic recurrence in HCC
[49]. However, AR expression has also been reported to be associated to small tumor size, but
not with a higher rate of recurrence [28]. More recent data indicate that suppression of
androgen or AR signals also led to an increase in the number of infiltrating cells, such as
macrophages as well as B or T-cells [50], which shows diverse and important roles in the
promotion of HCC tumorigenicity [51]. Although there is few data on the effect of anti-
androgens in HCC patients, it has been suggested that anti-androgen therapy may have some
benefit in patients with androgen-positive tumors [52]. Likewise, recently it has been reported
that a multicenter trial with anti-androgens in HCC male patients, has been interrupted
because of digestive side effects [39]. Nevertheless, further studies will be necessary to assess
whether AR status may be a useful marker to select more accurately candidate patients to
further anti-androgenic therapies. Notably, it has been reported that expression of androgen-
induced proteins, such as apolipoprotein D or Zinc-alpha2-glycoprotein, is associated with
poor prognosis in HCC.
Apolipoprotein D (ApoD) is an androgen-induced protein increased in both prostate and
breast cancer cells [53-55]. A report of Utsunomiya et al. showed that low ApoD expression
correlated significantly with less-differentiated HCCs and therefore with a worse prognosis
of patients [56]. However, we did not found any relationship between ApoD expression and
the hormonal receptor status in HCC [23]. Nevertheless, further studies will be also necessary
in order to assess the possible value of ApoD as a biological marker of androgen response and/
or other hormonal pathways in HCC. Thus, with regard to this latter aspect, although ApoD
is an androgen-regulated protein, it can also been induced by other hormonal steroids or
substances such as glucocorticoids, retinoic acid or 1,25-dihydroxyvitamin D3, that might be
involved in the regulation of this ApoD in human tumors [54,57-58]. This is relevant since it
has been described that both retinoid and glucocorticoid receptors have been also detected in
HCC [59-60], and that preliminary data show that retinoids are considered of clinical interest
as cancer chemotherapeutic agents in advanced HCC [61].
Zinc-alpha2-glycoprotein (ZA2G) is also an androgen-induced protein increased in breast
cancer [58,62]. Recently, ZA2G expression was found to be decreased in HCC tissues at both
mRNA and protein levels. Moreover, low expression of ZA2G was notably more prevalent in
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patients with poor tumor differentiation, advanced liver cirrhosis, high serum alpha fetopro‐
tein (AFP) level and shorter survival time. These results suggest that ZA2G may be a promising
novel prognostic biomarker for HCC [63], and advocate for the need for validation studies.
Hormone
Receptor/
mRNA
Valuation
parameters Treatment n Clinical outcomes Year Reference
ER (previous
patient
group)
Tumor growth Progestin 5 Tumor regression in 2 1982 [124]
NA
Anti-tumoral
effect.
Survival.
Tamoxifen 20 mg
twice daily. 33
No effect on the tumor,
in 8 remained stable
between 5 and 13
months. Prolonged
survival in 4 patients
(over 18 months).
1990 [154]
NA
Anti-tumoral
effect.
Survival.
Tamoxifen
20 mg daily.
120
(placebo =
62)
No effect on the tumor.
No effect on survival. 1995 [155]
Wild type and
variant ER
RNA m
Tumor growth.
Tamoxifen
80 mg daily in
patients with wild-ERs
or megestrol
160 mg daily in
patients with variant
ERs.
8 patients, 4
with wild ERs
and 4 with
variant ERs.
Tumor regression to half
size in patients with wild
type ERs following
tamoxifen treatment.
Megestrol slowed down
tumor growth in tumors
with variant ERs.
1996 [30]
ER y PR Survival. Tamoxifen.
119
(placebo =
58)
No effects on survival,
regardless of the type of
receptor expressed.
2000 [156]
Variant ER
mRNA.
Tumor growth.
Survival.
Megestrol
160 mg daily.
45 (placebo =
24).
Significantly slowed
down tumor growth and
improved survival in
treated patients than
placebo group.
2001 [157]
NA Survival.Quality of life.
Tamoxifen
120 mg or 60 mg
daily.
329
No effect on survival or
on quality of life.
Deleterious effects with
the higher dose.
2002 [158]
ER= Estrogen receptor. NA=information not available. PR= Progesterone Receptor.
Table 4. Results of hormonal treatment in hepatocellular carcinoma
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Recent data indicates that estrogens attenuate tumor progression in HCC in vivo by reducing
tumor cell invasion, arresting cell cycle progression, and promoting apoptosis, which is
characterized by an increased expression of cleaved caspase-3, and by a decrease in the
expression of Proliferating Cell Nuclear Antigen (PCNA), cyclin A, cyclin D1, Bcl-2, and matrix
metalloproteases (MMP) 2 and 9 [64]. It is relevant the data indicating that steroid hormones,
such as estrogens, may inhibit MMPs in several experimental models [65-67]. This may be of
great importance due to MMPs are proteolytic enzymes which participate in the degradation
of the stromal connective tissue and basement membrane component, therefore facilitating
tumor invasion and metastasis. Here, we show a negative relationship between ER expression
and MMP2, MMP-9 or MMP-11 expression in HCC (Figure 1).
Figure 1. Relationship between ER expression and median score values of MMP2, MMP-9 or MMP-11 expression in
HCC.
5. Metalloproteases and their inhibitors
Degradation of the stromal connective tissue and basement membrane components are key
elements in tumor invasion and metastasis. Some components of the extracelluar matrix,
particularly interstitial collagens, are very resistant to proteolytic attacks, being degraded only
by matrix metalloproteases (MMPs) [68].
The human MMP family currently consists of 28 members of homologous zinc-dependent
endopeptidases, which can be divided into eight structural classes or, based on their substrate
specificity and primary structure, into the more familiar subgroups of collagenases (MMP-1,
-8 and -13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10, -11), membrane-associated
MMPs (MMP-14, -15, -16, -17, -23, -24, -25) and other novel MMPs [69-71]. MMPs are synthe‐
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sized as inactive zymogens, which are then activated predominantly pericellularly by other
MMPs or by serine-proteases. MMPs’ activity is specifically inhibited by the so-called tissue
inhibitors of metalloproteases (TIMPs). Currently, four different TIMPs are known to exist:
TIMP-1, -2, -3 and -4. In addition, there are other two additional aspects conferring relevance
to this enzymatic system in cancer biology. First, MMPs are able to impact on tumor cell
behavior in vivo as a consequence of their ability to cleave growth factors, cell surface receptors,
cell adhesion molecules, or chemokines/cytoquines [72-77]. Furthermore, by cleaving proa‐
poptotic factors, MMPs may induce a more aggressive phenotype via generation of apoptotic
resistant cells [78]. MMPs may also regulate angiogenesis in cancer, both positively through
their ability to mobilize or activate proangiogenic factors [79-80], and negatively via generation
of angiogenesis inhibitors, such as angiostatin and endostatin, cleaved from large protein
precursors [81-83]. Second, it is now assumed that TIMPs are multifactorial proteins also
involved in the induction of proliferation and the inhibition of apoptosis [84-85].
Previous studies have shown the expression of several MMPs in HCC [86-100]. These findings
have a great interest because HCC is characterized by a disposition for vascular invasion and
high metastatic potential, thus leading to high incidence of early postoperative recurrence and
poor survival [101-102]. Although there is no basal membrane in the liver, HCC cancer cells
grow surrounded by extracellular matrix proteins secreted as a consequence of cirrhosis, and
therefore proteolytic activity is required to allow HCC cells to penetrate and cross over such
tissue boundaries [103]. In fact, several studies have suggested the significance of some MMPs
in the malignant behavior of HCC, such as MMP-2 [86-93], MMP-7 [88,94], MMP-9
[95-97,91,93,104], MMP-12 [105] or MMP-14 (MT1-MMP) [98,91,99-100]. In these studies,
MMPs were associated with several parameters indicative of tumor aggressiveness and poor
prognosis, although the cellular type expressing each factor (tumor cell and/or peritumor
stromal cell) was not specifically considered.
There are few available data referring to the integrated expression of these factors in relation
with  HCC.  In  this  context,  we  have  described  new  findings  about  MMPs  and  TIMPs
expressions in HCC, together with an important expression by tumor stromal cells, as well
as their clinical relevance. It is known that MMPs expression in neoplastic tissues is high
due to regulation, in a paracrine manner, by growth factors and cytokines secreted by either
tumor or  stromal cells  [106].  Nevertheless,  high MMPs and TIMPs expression by HCCs
tissues may be also due to the interplay between transformed cells and their microenviron‐
ment,  particularly  the  surrounding  extracellular  matrix.  In  human  livers,  fibrogenesis
underlies the development of HCCs in at least 90% of cases [107],  and HCC is typically
surrounded by a fibrous capsule at an early stage [108]. In addition, several studies have
shown  that  some  MMPs  (MMP-1,  -2,  -9  and  -13)  and  TIMPs  (TIMP-1  and  -2)  are  in‐
volved in the liver fibrosis processes [90,109-112]. It has been demonstrated that extracellu‐
lar matrix deposition induces overexpression of MMPs and TIMPs, such as MMP-2, secreted
by human mesenchymal cells but also by hepatoma cells [87].
Recently we reported that immunostaining for MMPs and TIMPs was localized predominantly
in tumor cells, but also in peritumor stromal cells in a significant percentage of cases. However,
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we found no stromal expression of MMPs or TIMPs in normal liver samples [113]. We also
found a positive and noteworthy association between MMP-1 expression by fibroblasts or by
mononuclear inflammatory cells (MICs) and a larger tumor size. In addition, our data showed
that MMP-1 expression by stromal fibroblasts, as well as the expression of MMP-13, TIMP-1
and 2, by MICs, were significantly associated with a shorter overall survival (Figure 2) [113].
Figure 2. Kaplan-Meier survival curves as function of the expression by fibroblasts cells of MMP-1 (A); expression by
MIC of MMP-13 (B), TIMP-1 (C) and TIMP-2 (D).
There are discrepancies between different studies regarding the prognostic significance of
several  of  these  factors  in  HCC,  such  as  MMP-9  and  MMP-2  expression  in  stromal
compartments  [113,93].  Nevertheless,  it  is  worth  considering  the  existence  of  possible
differences in MMPs or TIMPs expression between different patient’s populations. Thus,
for example, in Asian countries HCC originates more frequently in healthy liver tissues,
with less incidence of cirrhosis, than in Europe, whereas in the Mediterranean area as well
as in the North American countries liver HCC only develops in chronically injured livers,
where altered turn-over and increased deposition of ECM proteins has been described. In
a such environment, upregulation of MMPs and TIMPs has been reported and it is possible
for them to play an important role in the rearrangement of the liver tissue architecture an
aspect that could influence the different expression pattern of MMPs and TIMPs in stromal
HCC cells [110,114].
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On the other hand, a decrease on TIMP-2 and -3 expression has been reported to be associated
with invasion and metastases in HCC [115-116]. Certainly, if TIMPs inhibit MMPs in vivo, it
should be expected that high levels of these inhibitors would prevent tumor progression and
thus to be related with good outcome in cancer patients. However, TIMPs are multifunctional
proteins that in addition to its MMP-inhibitory effect also shown distinct tumor-stimulatory
functions, such as the induction of proliferation and the inhibition of apoptosis [84]. Thus, it
is of note that TIMP-1 and -2 expressions by stromal cells were associated with shortened
overall survival[113]. Accordingly, it has been reported that TIMP-1 overexpression leads to
an increase of hepatoma cells migration [117], and also that it is associated with invasion and
metastases in HCC [115,117].
Figure 3. Graphical representation of two-dimensional unsupervised hierarchical clustering results on immunohisto‐
chemistry expression (score values) profile in 10 proteins (MMPs and TIMPs) in 30 samples of HCC tissue. Rows: tumor
samples; columns: MMPs and TIMPs. Protein expressions are depicted according to a color scale: red: positive staining;
green: negative staining; gray: missing data. At right bank of the figure is represented the overall survival status for
each patient (0, alive; 1, death due tumor progression).
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The unsupervised hierarchical cluster analysis of MMPs/TIMPs expressions in HCCs led us to
identify 2 well-defined clusters of cases (Figure 3): one with low expression of MMPs and
TIMPs (Group 1), and another with high expression of these factors (Group 2). This classifi‐
cation could have biological interest in order to identify patient candidates to new therapies
based on enzymatic MMP inhibition. With regard to this, although there are no published data
about use of MMP inhibitors in HCC, recently it has been reported that decreased MMP activity
mediated by statins reduced progression and limits metastatic diffusion of established HCC
[118]. Likewise, it was demonstrated that blocking the tumor-related glycoprotein HAb18G/
CD147 by gene silence in HCC cells or with HA18 monoclonal antibody, resulted in a sup‐
pressive effect on MMP secretion and cell invasion [119]. More recent studies have shown an
antimetastatic effect of Norcantharidin on HCC by transcriptional inhibition of MMP-9 [120],
as well as a metastasis inhibition of HCC cells due to down-regulation of Osteopontin via a
mechanism involving MMP-2 and urinary plasminogen activator (uPA) [121].
6. Conclusion
In summary, we consider that expression analysis of steroid hormone receptors, MMPs and
TIMPs, contributes to a better knowledge in the biological characterization of HCC and
highlights the need for further studies exploring new therapeutic targets for this common
tumor.
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